It is certainly within the bounds of reality that MO does in some way effect the R-I results...What has been observed is a 7% increase in LDL-C in the placebo arm...That could partially be explained by a small reduction of LDL-C in the active arm...caused by EPA...Or because the mineral oil was inhibiting the absorption of statins...Either way the effect would be very small...about 5mg LDL-C and could not possibibly had a very big effect on the risk reductions..
The increase of LDL-C did not correlate exactly with the CVD event risk in the placebo arm..meaning patients with the highest LDL-Cs did not have the highest CVD event risk...
One way to test the MO question would be to run a twelve week trial using two arms...You could treat one arm with a fixed dose of statins...and another arm getting statins and and a dose of mineral oil which was the same (4 gms/day) as that used in the R-I trial...You could run the trial for 12 weeks..(similar to MARINE and ANCHOR...Then determine the difference in LDL-C levels between the two arms..
News 
Market Data 
Discover 
AI
